通策医疗(600763)：25Q1稳健增长 全年有望持续向好

Core Insights - The company reported a revenue of 2.874 billion yuan for 2024, reflecting a year-on-year increase of 0.96%, and a net profit attributable to shareholders of 501 million yuan, up 0.20% year-on-year [1] - In Q1 2025, the company achieved a revenue of 745 million yuan, representing a year-on-year growth of 5.11%, with a net profit of 184 million yuan, up 6.22% year-on-year [1] Business Analysis - The planting business showed steady growth with a revenue of 530 million yuan in 2024, an increase of 10.60% year-on-year, accounting for 19.39% of total revenue, driven by demand release from price reductions post-collective procurement [2] - The orthodontics business saw a revenue decline of 5.05% to 474 million yuan, with invisible correction accounting for approximately 15% of this segment [2] - Pediatric business revenue was 501 million yuan, up 0.29% year-on-year, while repair business revenue reached 462 million yuan, increasing by 1.53% [2] - The company expanded its "Dandelion Plan" in the province, adding 3 new branches in 2024, bringing the total to 44, covering all 11 prefecture-level cities in Zhejiang [2] - Revenue from outside the province reached 277 million yuan, a year-on-year increase of 4.83%, with a gross margin improvement of 4.72 percentage points to 29.51% [2] Digitalization and Management - The company is advancing its digital transformation by leveraging its stake in Ren Technology to create an AI platform (MindHub), enhancing efficiency and service quality across clinical diagnosis, patient services, and operational management [3] - Continuous efforts in cost reduction and efficiency improvement are being made through refined operations, structural optimization, and digital empowerment [3] Profit Forecast and Valuation - Due to external consumption environment factors, the company has revised its profit forecast, expecting net profits attributable to shareholders of 537 million yuan, 574 million yuan, and 610 million yuan for 2025-2027, representing year-on-year growth of 7%, 7%, and 6% respectively [4] - The expected EPS for the same period is 1.20, 1.28, and 1.36 yuan, with corresponding PE ratios of 33, 31, and 29 times [4]